HYFT

MindWalk Holdings Corp.

$1.03

-4.63%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company is headquartered in Austin, Texas.

Source: Yahoo Finance

Market Cap$49M

Dividend Yield0.00%

AnalystsStrong Buy+320.7% target

Beta1.51

AI summary

Price & performance

1M-32.9%

3M-24.2%

YTD-50.5%

1Y-44.8%

52-week range—

Beta1.51

Full chart and returns against a benchmark

Q-Score

55/ 100

Quality against peers; 50 is the peer median.

Growth60

Risk45

Performance50

Valuation54

Profitability61

Leverage—

Sentiment43

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$17.7M-1.1%

Net income-$21.9M

Net margin-123.3%-16.8 pts

Historical fundamentals

Red flags in filings

2active red flags

Going-concern doubtJul 23, 2026

Material weakness in controlsJul 23, 2026

Filings, findings and the timeline

Revenue exposure

34%of revenue from outside the US

United States66%

Europe18%

All Other Countries7%

Regions, segments, customers and suppliers

Valuation

HYFTIndustryP/E—89.69P/S2.3611.88EV/EBITDA—67.10P/B4.456.22PEG—4.02

Dividend yield0.00%

Every valuation metric

Earnings

Dec 15next report

EPS estimate—

Beats (last 4 quarters)—

Average surprise—

EPS revisions (30d)—

Every quarter against its estimate

Historical Fundamentals

Revenue

Net Income

Net Margin

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q1 2026	vs a year before
Revenue	$17.7M	-1.1%	$3.1M	—
Net Income	-$21.9M	—	-$2.9M	—
Net Margin	-123.3%	-16.8 pts	-94.5%	—

Earnings

The next report, and the record against analysts' estimates.

Next EPS estimate—

Beats (last 4 quarters)—

Average surprise—

EPS revisions (30d)—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 5755

Growth

Industry 7960

Risk

Industry 5545

Performance

Industry 6650

Valuation

Industry 2554

Profitability

Industry 4761

Sentiment

Industry 6043

Key Metrics

Fundamentals: trailing twelve months to Jan 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.780.57

Market Cap

49M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 693.1KSM 741.7K237.3K

Industry Market Share

0.00%

Sector Market Share

0.00%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/E	EV/EBITDA	P/S	P/B	FCF yield	Revenue growth	ROE	Debt/equity
HYFTMindWalk Holdings Corp.	$49M	—	—	2.4	4.4	-18.4%	109.9%	-90.5%	0.0
PLRXPliant Therapeutics, Inc.	$48.7M	—	—	—	0.3	-145.7%	—	-62.8%	0.0
ATNMActinium Pharmaceuticals, Inc.	$49.4M	4.4	1.3	—	1.6	-46.1%	—	37.3%	0.0
GRDXGridAI Technologies Corp.	$49.4M	—	—	—	3.3	-16.4%	—	-145.3%	0.0
ONCYOncolytics Biotech Inc.	$50.1M	—	—	—	—	-53.4%	—	—	—
IBIOiBio, Inc.	$50.2M	—	—	—	0.6	-47.4%	-75.0%	-38.6%	0.0
MREOMereo BioPharma Group plc	$47.6M	—	—	59.5	2.0	-46.4%	60.0%	-113.6%	0.0
RNTXRein Therapeutics Inc.	$50.9M	—	—	—	0.9	-37.0%	—	-90.1%	0.0
HOWLWerewolf Therapeutics, Inc.	$47.1M	—	—	—	2.9	-63.9%	—	-212.5%	2.0
Industry median		11.7	20.2	7.7	2.2	-22.3%	12.8%	-60.8%	0.0
HYFT percentile		—	—	19th	72nd	55th	81st	36th	39th